Risk factors

ArriVent BioPharma faces critical geographic and supplier dependencies in China for its lead product candidate firmonertinib. Intellectual property and licensing agreements heavily dictate commercial success and financial obligations. Regulatory pricing pressures and cybersecurity threats present growing operational hurdles.

Late-stage HCV development now includes commercial launch supply manufacturing and NDA preparation for bemnifosbuvir/ruzasvir.

BridgeBio Oncology Therapeutics transitioned from a SPAC shell company to an operating biopharmaceutical firm following its business combination in May 2024.

Merger-related risks disappeared, while BCP added risks covering AI, cybersecurity, data protection, pandemics, and concentrated investments.

The company relies heavily on parking assets and debt financing, including a March 2026 revolving credit facility maturity.

Bioventus faces new derivative litigation risks and risks from evolving international tariff policies.

Founder Gary Bowman announced his retirement for 2026, triggering key executive succession risks. Bowman will lose its Emerging Growth Company status on December 31, 2026, increasing compliance costs. The risk profile expands into artificial intelligence challenges and data privacy regulations like the CCPA.

Camp4 added specific disclosures on regulatory safety uncertainties for novel regulatory RNA-targeting ASOs, supply chain risks from Chinese biotech scrutiny under the BIOSECURE Act, and potential competition from established firms like Alnylam and Ionis.

Concentration in commercial real estate loans exposes Carter Bankshares to elevated credit risk and potential default losses.

Cherry Hill added trade policy risks after completing its transition to a self-managed company by terminating its management agreement with CHMM.

International markets represented approximately 58% of total sales for the year ended December 31, 2025. Restructuring actions initiated since 2023 continue into 2026. Mr. Kanders beneficially owns 8,124,220 shares as of March 2, 2026.

Climb Bio faces heightened trade tariff risks, especially on imported drug materials from China under new 2025 administration proposals. Cash reserves of $160.7 million are projected to fund operations into 2028, but heavy milestone payment obligations continue. International expansion introduces complex global privacy, tax, and regulatory hurdles.